BEIJING, 25 Feb – RIA Novosti. The State Food and Drug Administration of China has approved for widespread use two more vaccines for coronavirus infection COVID-19, developed by CanSino Biologics and the Wuhan Research Institute of Biologicals.
Previously, similar permission received inactivated vaccines from Beijing Kexing Zhongwei Biotechnology (part of Sinovac) and China National Biotech Group (part of Sinopharm).
“The State Food and Drug Administration of China on February 25 approved an application for registration of the recombinant vaccine against COVID-19 (based on adenoviral vector) Ad5-nCoV from CanSino Biologics,” the ministry said in a statement.
However, the agency said Thursday it also approved an application for registration of an inactivated vaccine from the Wuhan Research Institute of Biologicals.